These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 37075362)

  • 21. Two novel mutations of the LPL gene in two Chinese family cases with familial chylomicronemia syndrome.
    Wang M; Zhou Y; He X; Deng C; Liu X; Li J; Zhou L; Li Y; Zhang Y; Liu H; Li L
    Clin Chim Acta; 2021 Oct; 521():264-271. PubMed ID: 34324844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical, biochemical and molecular analysis of two infants with familial chylomicronemia syndrome.
    Zhang Y; Zhou J; Zheng W; Lan Z; Huang Z; Yang Q; Liu C; Gao R; Zhang Y
    Lipids Health Dis; 2016 May; 15():88. PubMed ID: 27153815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
    Chait A; Eckel RH
    Ann Intern Med; 2019 May; 170(9):626-634. PubMed ID: 31035285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1.
    Ahmad Z; Wilson DP
    J Clin Lipidol; 2014; 8(6):635-639. PubMed ID: 25499947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The molecular basis of familial chylomicronemia.
    Ameis D; Schotz C; Greten H
    Z Gastroenterol Verh; 1991 Mar; 26():102-3. PubMed ID: 1714114
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of lipoprotein lipase activity measurement in the diagnosis of familial chylomicronemia syndrome.
    Rioja J; Ariza MJ; Benítez-Toledo MJ; Espíldora-Hernández J; Coca-Prieto I; Arrobas-Velilla T; Camacho A; Olivecrona G; Sánchez-Chaparro MÁ; Valdivielso P
    J Clin Lipidol; 2023; 17(2):272-280. PubMed ID: 36813655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of three known and one novel LPL variants in patients with type I hyperlipoproteinemia.
    Caddeo A; Mancina RM; Pirazzi C; Russo C; Sasidharan K; Sandstedt J; Maurotti S; Montalcini T; Pujia A; Leren TP; Romeo S; Pingitore P
    Nutr Metab Cardiovasc Dis; 2018 Feb; 28(2):158-164. PubMed ID: 29288010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial chylomicronemia syndrome- an uncommon cause of acute pancreatitis with encephalopathy.
    Kota SK; Kota SK; Jammula S; Modi KD
    Indian J Gastroenterol; 2012 Sep; 31(5):277-9. PubMed ID: 23081844
    [No Abstract]   [Full Text] [Related]  

  • 29. Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia.
    Paquette M; Bernard S; Hegele RA; Baass A
    Atherosclerosis; 2019 Apr; 283():137-142. PubMed ID: 30655019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Familial chylomicronemia syndrome: a case report.
    Susheela AT; Vadakapet P; Pillai L; Thampi S
    J Med Case Rep; 2021 Jan; 15(1):5. PubMed ID: 33419463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comprehensive Update on the Chylomicronemia Syndrome.
    Goldberg RB; Chait A
    Front Endocrinol (Lausanne); 2020; 11():593931. PubMed ID: 33193106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chylomicronemia syndrome.
    Rao AG; Konda C; Jhamnani KK
    Indian J Dermatol Venereol Leprol; 2009; 75(2):220. PubMed ID: 19293528
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting APOC3 in the familial chylomicronemia syndrome.
    Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
    N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia.
    Brunzell JD; Bierman EL
    Med Clin North Am; 1982 Mar; 66(2):455-68. PubMed ID: 7040847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase.
    Al-Shali K; Wang J; Fellows F; Huff MW; Wolfe BM; Hegele RA
    Clin Biochem; 2002 Mar; 35(2):125-30. PubMed ID: 11983347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Volanesorsen for treatment of familial chylomicronemia syndrome.
    Lazarte J; Hegele RA
    Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic.
    Rioja J; Ariza MJ; García-Casares N; Coca-Prieto I; Arrobas T; Muñiz-Grijalvo O; Mangas A; Ibarretxe D; Sánchez-Chaparro MÁ; Valdivielso P
    Eur J Clin Invest; 2020 Dec; 50(12):e13345. PubMed ID: 32649781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Diagnosis and Management of Primary Chylomicronemia.
    Okazaki H; Gotoda T; Ogura M; Ishibashi S; Inagaki K; Daida H; Hayashi T; Hori M; Masuda D; Matsuki K; Yokoyama S; Harada-Shiba M
    J Atheroscler Thromb; 2021 Sep; 28(9):883-904. PubMed ID: 33980761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
    Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
    Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis and management of type I and type V hyperlipoproteinemia.
    Gotoda T; Shirai K; Ohta T; Kobayashi J; Yokoyama S; Oikawa S; Bujo H; Ishibashi S; Arai H; Yamashita S; Harada-Shiba M; Eto M; Hayashi T; Sone H; Suzuki H; Yamada N;
    J Atheroscler Thromb; 2012; 19(1):1-12. PubMed ID: 22129523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.